Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 study Meeting Abstract
| Authors: | Eskander, R.; Sill, M.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M.; Cantuaria, G.; Girda, E.; Mathews, C.; Kavecansky, J.; Leath, C.; Gien, L.; Hinchcliff, E.; Lele, S.; Lele, S.; Landrum, L.; Backes, F.; O'Cearbhaill, R.; Liu, R.; Hill, E.; Thaker, P.; John, V.; Powell, M.; Aghajanian, C. |
| Abstract Title: | Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 study |
| Meeting Title: | Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer (54th Annual Meeting) |
| Journal Title: | Gynecologic Oncology |
| Volume: | 176 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Mar 25-28 |
| Meeting Location: | Tampa, FL |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S42 |
| End Page: | S43 |
| Language: | English |
| ACCESSION: | WOS:001079556100060 |
| DOI: | 10.1016/j.ygyno.2023.06.523 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA 10 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
273O'Cearbhaill -
613Aghajanian
Related MSK Work